Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma

Martine Bagot; Stéphane Dalle; Lubomir Sokol; Athansios Tsianakas; Amy Musiek; Pablo L. Ortiz-Romero; Brian Poligone; Madeleine Duvic; Craig Elmets; Mollie Leoni; Karen Dwyer; Takahiro Ito; Fiona Herr; Youn H. Kim

doi:10.1111/dth.15634

Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma

Martine Bagot
, Stéphane Dalle
, Lubomir Sokol
, Athansios Tsianakas
, Amy Musiek
, Pablo L. Ortiz-Romero
, Brian Poligone
, Madeleine Duvic
, Craig Elmets
, Mollie Leoni
, Karen Dwyer
, Takahiro Ito
, Fiona Herr
, Youn H. Kim

Research output: Contribution to journal › Letter › peer-review

Original language	English
Article number	e15634
Journal	Dermatologic Therapy
Volume	35
Issue number	8
DOIs	https://doi.org/10.1111/dth.15634
State	Published - Aug 2022

Access to Document

10.1111/dth.15634

Cite this

Bagot, M., Dalle, S., Sokol, L., Tsianakas, A., Musiek, A., Ortiz-Romero, P. L., Poligone, B., Duvic, M., Elmets, C., Leoni, M., Dwyer, K., Ito, T., Herr, F., & Kim, Y. H. (2022). Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma. Dermatologic Therapy, 35(8), Article e15634. https://doi.org/10.1111/dth.15634

@article{37d390d3f738467284c39ce574c91b69,

title = "Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma",

author = "Martine Bagot and St{\'e}phane Dalle and Lubomir Sokol and Athansios Tsianakas and Amy Musiek and Ortiz-Romero, \{Pablo L.\} and Brian Poligone and Madeleine Duvic and Craig Elmets and Mollie Leoni and Karen Dwyer and Takahiro Ito and Fiona Herr and Kim, \{Youn H.\}",

note = "Funding Information: Kyowa Kirin, Inc.",

year = "2022",

month = aug,

doi = "10.1111/dth.15634",

language = "English",

volume = "35",

journal = "Dermatologic Therapy",

issn = "1396-0296",

number = "8",

}

Bagot, M, Dalle, S, Sokol, L, Tsianakas, A, Musiek, A, Ortiz-Romero, PL, Poligone, B, Duvic, M, Elmets, C, Leoni, M, Dwyer, K, Ito, T, Herr, F & Kim, YH 2022, 'Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma', Dermatologic Therapy, vol. 35, no. 8, e15634. https://doi.org/10.1111/dth.15634

TY - JOUR

T1 - Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab

T2 - Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma

AU - Bagot, Martine

AU - Dalle, Stéphane

AU - Sokol, Lubomir

AU - Tsianakas, Athansios

AU - Musiek, Amy

AU - Ortiz-Romero, Pablo L.

AU - Poligone, Brian

AU - Duvic, Madeleine

AU - Elmets, Craig

AU - Leoni, Mollie

AU - Dwyer, Karen

AU - Ito, Takahiro

AU - Herr, Fiona

AU - Kim, Youn H.

N1 - Funding Information: Kyowa Kirin, Inc.

PY - 2022/8

Y1 - 2022/8

UR - https://www.scopus.com/pages/publications/85132899953

U2 - 10.1111/dth.15634

DO - 10.1111/dth.15634

M3 - Letter

C2 - 35695215

AN - SCOPUS:85132899953

SN - 1396-0296

VL - 35

JO - Dermatologic Therapy

JF - Dermatologic Therapy

IS - 8

M1 - e15634

ER -

Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma

Access to Document

Other files and links

Cite this